EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SELLAS Life Sciences Group's Enterprise Value is $63.24 Mil.
SELLAS Life Sciences Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-30.04 Mil. Therefore, SELLAS Life Sciences Group's EV-to-FCF for today is -2.11.
The historical rank and industry rank for SELLAS Life Sciences Group's EV-to-FCF or its related term are showing as below:
SLS'
s EV-to-FCF Range Over the Past 10 Years
Min: -27.42 Med: -0.66 Max: 0.97
Current: -2.11
During the past 13 years, the highest EV-to-FCF of SELLAS Life Sciences Group was 0.97. The lowest was -27.42. And the median was -0.66.
SLS's EV-to-FCF is ranked worse than 100% of 372
companies
in the Biotechnology industry
Industry Median: 8.36
vs SLS: -2.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SELLAS Life Sciences Group's EV-to-FCF
For the Biotechnology subindustry, SELLAS Life Sciences Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's EV-to-FCF falls into.
SELLAS Life Sciences Group's current Enterprise Value is $63.24 Mil.
SELLAS Life Sciences Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (NAS:SLS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
SELLAS Life Sciences Group's PE Ratio for today is calculated as:
SELLAS Life Sciences Group's share price for today is $1.40.
SELLAS Life Sciences Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SELLAS Life Sciences Group EV-to-FCF Related Terms
Thank you for viewing the detailed overview of SELLAS Life Sciences Group's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SLS has been successfully added to your 